Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24821656 | 1.00 | NR1H2 (0.42) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL1639634 | 1.00 | NR1H2 (0.42) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4040236 | 0.88 | NR1H2 (0.37) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4040230 | 0.88 | NR1H2 (0.37) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4049137 | 0.86 | PREP (0.35) | NR1H2PREPCTSKLMNANPSR1 | |
| SCHEMBL4049132 | 0.86 | PREP (0.35) | NR1H2PREPCTSKLMNANPSR1 | |
| SCHEMBL22950853 | 0.83 | PREP (0.35) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4042751 | 0.82 | LMNA (0.36) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL13944483 | 0.82 | CTSK (0.42) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4197155 | 0.82 | CTSK (0.42) | NR1H2MEN1KMT2APREPCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027068-A | Compound containing bridged ring and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117430619-A | Pyrazolopyridine compound and preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| WO-2022161448-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-08-04 | — | — | WO | disclosed |
| EP-4003355-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114173787-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 杨森科学爱尔兰无限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021018237-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-02-04 | — | — | WO | disclosed |
| EP-2705035-B1 | TRICYCLIC PYRAZOLE SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160324865-A1 | TRICYCLIC PYRAZOLE SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-11-10 | — | — | US | disclosed |
| US-9242997-B2 | Tricyclic pyrazole sulphonamide compunds and methods of making and using same | ZAFGEN, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20120277186-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2516446-A2 | SUBSTITUTED HEXAHYDROCHROMENO[3,4-B]PYRROLES WITH AFFINITY FOR THE SEROTONIN RECEPTOR (5-HT) FAMILY | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011087713-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20090005575-A1 | Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles | AMURA THERAPEUTICS LTD. (GB) | 2009-01-01 | — | — | US | disclosed |
| EP-1917266-A1 | PREPARATION OF DIAZAPENTALENE DERIVATIVES VIA EPOXYDATION OF DIHYDROPYRROLES | Amura Therapeutics Limited (GB) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007017698-A1 | PREPARATION OF DIAZAPENTALENE DERIVATIVES VIA EPOXYDATION OF DIHYDROPYRROLES | AMURA THERAPEUTICS LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005575-A1 | Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles | PTGDR2, PTGER2, PTGDR | NR1H2 384/4885MEN1 1777/4885KMT2A 4154/4885 |
| US-20160324865-A1 | TRICYCLIC PYRAZOLE SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, ANPEP, DPP4 | NR1H2 4298/4885MEN1 2364/4885KMT2A 870/4885 |
| US-20120277186-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP11B2, CYP11B1, CYP4A11 | NR1H2 456/4885MEN1 672/4885KMT2A 4628/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | NR1H2 106/4885MEN1 3247/4885KMT2A 3867/4885 |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | NR1H2 142/4885MEN1 4074/4885KMT2A 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.